Genfit S.A. (GNFT)
3.52
0.10 (2.92%)
At close: Apr 01, 2025, 3:33 PM
2.92% (1D)
| Bid | 3.15 |
| Market Cap | 175.73M |
| Revenue (ttm) | 75.63M |
| Net Income (ttm) | 30.42M |
| EPS (ttm) | 0.4 |
| PE Ratio (ttm) | 8.81 |
| Forward PE | -4.74 |
| Analyst | Buy |
| Ask | 3.63 |
| Volume | 24,185 |
| Avg. Volume (20D) | 9,168.5 |
| Open | 3.53 |
| Previous Close | 3.42 |
| Day's Range | 3.39 - 3.54 |
| 52-Week Range | 3.11 - 6.42 |
| Beta | 1.07 |
About GNFT
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat ...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 27, 2019
Employees 169
Stock Exchange NASDAQ
Ticker Symbol GNFT
Website https://www.genfit.com
Analyst Forecast
According to 1 analyst ratings, the average rating for GNFT stock is "Buy." The 12-month stock price forecast is $13, which is an increase of 268.88% from the latest price.
Stock Forecasts6 months ago
+15.51%
GENFIT shares are trading higher. The company repo...
Unlock content with
Pro Subscription
